Ronovo Surgical develops Carina™, a flagship modular robotic surgery platform for minimally invasive procedures. Carina received regulatory approval from China’s National Medical Products Administration (NMPA) in March 2025 with a first-time filing covering General Surgery, Gynecology, Urology, and Thoracic Surgery. Its configurable modular architecture is designed to address flexibility, adaptability and affordability challenges posed by legacy robotic systems. Ronovo has initiated global expansion with regulatory submissions underway in Europe and South America and has received enthusiastic feedback from international key opinion leaders. Financially, the company closed a $67 million Series D led by JJDC and has raised over $100 million in 2025, including a Series C earlier in the year led by Granite Asia. Ronovo also signed a targeted collaboration agreement with Johnson & Johnson Medical (Shanghai) Ltd. to offer Carina alongside J&J MedTech surgical technologies in portions of the China market to accelerate commercialization. Ruilong Surgical focuses on a modular laparoscopic surgical-robot platform, centered on its Haishan‑1® system along with an imaging system and surgical instruments. The company emphasizes multi-specialty clinical applicability, lower learning curve and improved cost-effectiveness for robotic-assisted surgery. Over the past three years it progressed Haishan‑1® from concept to regulatory testing, completed GLP animal studies and concluded multi-center, multi-specialty human clinical trials in February 2024. Ruilong has filed more than 100 domestic and international patents and is preparing a registration submission. The company is building an industrialization campus of over 12,000 sqm covering manufacturing, clinical research and training centers to support commercialization. Ruilong pursues a dual strategy of independent R&D and global collaboration, has established a U.S. clinical center and plans to accelerate international expansion. Ronovo Surgical develops robotic and digital systems for minimally invasive laparoscopic surgery, and has exited stealth with its inaugural modular robotic platform, Carina™. Carina is built on proprietary technology to enable configurable robotic assistance across multiple surgical specialties. The system was developed with Chinese laparoscopic surgeons as the initial use case, and early discussions with KOLs in the US and Europe suggest potential for broader international adoption. Ronovo plans to accelerate multi-discipline clinical trials for Carina and strengthen R&D and clinical applications development. The company also intends to bolster its talent base and continue discussions with clinical KOLs, strategic partners and global investors at upcoming medtech conferences. Financially, Ronovo announced it has raised more than $50M to support these efforts. Ronovo Surgical, founded in Shanghai in 2019, develops minimally invasive (MIS) and digital surgery technologies and surgical robotics aimed at democratizing MIS across the Chinese market. The company was built by surgeons, medtech veterans, and robotics experts with experience at firms such as Intuitive Surgical, Johnson & Johnson, Medtronic and KUKA and emphasizes three pillars—simplicity, precision, and intelligence—in its product strategy. Ronovo is positioning its technology platform as a gateway to China for global MIS and digital surgery companies and is pursuing strategic global partnerships to accelerate development and commercialization. The firm has assembled a world-class R&D team and is working with renowned clinical KOLs as it advances its pipeline. Management says it will accelerate technology development and pursue multiple global strategic partnerships to support an accelerated path to commercialization. Ronovo aims to enable China’s hospitals with digital surgery solutions that optimize patient clinical outcomes and reduce health economic burden. Ronovo Surgical develops Carina™, a modular, configurable laparoscopic robotic platform designed in Shanghai that emphasizes modularity, configurability and compatibility. The company aims to expand Carina’s clinical applications across multiple surgical specialties and to commercialize the system in China and internationally. Ronovo says it stands at the cusp of multi‑specialty human clinical trials, roughly 2.5 years after beginning conceptual design. Leadership highlights a clinically driven design approach and a team with industry experience from companies such as Intuitive, Auris Health, KUKA, Medtronic and Smith+Nephew. The firm is pursuing a multi‑specialty roadmap to broaden access to robotic surgery and accelerate adoption by surgeons and hospitals worldwide.

Total raised

$184M

Funding rounds

5

Latest round

Series D

Latest activity

Sep 2025